Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacologic management of insomnia: Assessing the nonbenzodiazepine hypnotics
Autore:
Chow, SL; Tomlinson, B; Chow, MSS;
Indirizzi:
Buffalo Gen Hosp, Buffalo, NY 14203 USA Buffalo Gen Hosp Buffalo NY USA 14203 alo Gen Hosp, Buffalo, NY 14203 USA
Titolo Testata:
FORMULARY
fascicolo: 11, volume: 35, anno: 2000,
pagine: 894 -
SICI:
1082-801X(200011)35:11<894:PMOIAT>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
PSYCHIATRIC-DISORDERS; PSYCHOMOTOR PERFORMANCE; TREATMENT EFFICACY; SLEEP-DEPRIVATION; ACTING HYPNOTICS; DOUBLE-BLIND; ZOLPIDEM; TRIAZOLAM; ZALEPLON; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
65
Recensione:
Indirizzi per estratti:
Indirizzo: Chow, MSS Chinese Univ Hong Kong, Fac Med, Dept Pharm, Shatin, Hong Kong, Peoples R China Chinese Univ Hong Kong Shatin Hong Kong Peoples R China China
Citazione:
S.L. Chow et al., "Pharmacologic management of insomnia: Assessing the nonbenzodiazepine hypnotics", FORMULARY, 35(11), 2000, pp. 894

Abstract

The nonbenzodiazepine hypnotics zolpidem and zaleplon have more rapid absorption, metabolism, and elimination compared with most benzodiazepines. These proper ties contribute to shorter residual effects, which may make nonbenzodiazepines preferable for insomnia patients who need to be alert due to societal or occupational demands, who may have limited time before they must awaken, or who suffer from sleep-onset insomnia. Zalepion and zolpidem differ in several potentially important ways. While the two agents appear to reduce sleep latency and increase sleep duration to similar degrees, zaleplon produces less pronounced and less long-lasting benzodiazepine agonist effects (psychomotor/memory impairment and sedation) than zolpidem. It can also be taken after the patient has gone to bed and experiences difficulty falling asleep, provided the patient has 4 or more hours before resuming activity. Zolpidem, on the other hand, appeared to have some beneficial effect on sleep continuity in most clinical trials, consistent with its somewhat longer half-life relative to zaleplon. The two agents also have differing drug interaction profiles due to differing routes of metabolism.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:20:03